Peptide Clinical Trials

Name: Synptide Peptide Clinical Trials
Creator: Synptide
License: https://creativecommons.org/licenses/by/4.0/

Registered human trials for the research peptides we track, pulled from ClinicalTrials.gov. 12 of 85 are active. Many popular research peptides have little or no registered human trial evidence — which is itself worth knowing.

v1.0 · Updated 2026-07-12 · Source: ClinicalTrials.gov API v2 · 85 rows

Download CSV View JSON Browse the directory

No registered trials found for: GHK-Cu, GHRP-2, GHRP-6, Epitalon, Semax. Absence of a registry record is not proof no research exists, but it signals a thin human evidence base.

Trial	Compounds	Phase	Status	Enroll.	Start
Phase 3 Study of LUM-201 in Children With Growth Hormone DeficiencyNCT06948214	MK-677	Phase 3	Recruiting	150	2026-05-20
Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial InfarctionNCT07586865	Thymosin Beta-4	Phase 2	Not yet recruiting	189	2026-05-18
Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal TransplantationNCT07678073	MOTS-c	—	Recruiting	68	2026-03-01
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVDNCT07487363	TB-500, Thymosin Beta-4	Phase 1/Phase 2	Recruiting	80	2026-02-05
BPC 157 for Acute Hamstring Muscle Strain RepairNCT07437547	BPC-157	Phase 2	Recruiting	120	2026-02-02
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)NCT07481734	Tesamorelin	Phase 2	Recruiting	120	2026-02-02
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/ObesityNCT07505745	MOTS-c	Phase 2	Recruiting	120	2026-02-02
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIVNCT06554717	Sermorelin, Tesamorelin	Phase 2	Recruiting	100	2025-07-10
Cathelicidin LL-37 Relation to Potentially Malignant LesionsNCT06219330	LL-37	—	Completed	45	2023-07-01
Comparing the Efficacy of tDCS and tRNS to Improve Reading Skills in Children and Adolescents With DyslexiaNCT05832060	Selank	—	Unknown	24	2023-05-01
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2NCT05555589	Thymosin Beta-4	Phase 3	Recruiting	70	2023-04-11
The Impact of Ibutamoren on Nonalcoholic Fatty Liver DiseaseNCT05364684	MK-677	Phase 2	Completed	12	2022-08-10
Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial InfarctionNCT05984134	Thymosin Beta-4	Phase 2	Completed	90	2022-07-15
Peri-implant Vitamin D and Cathelicidin (LL-37) LevelsNCT06867250	LL-37	—	Completed	33	2021-04-01
Cathelicidin LL-37 Levels in the GCF and the Saliva of Smokers and Non-smokers With Stage III,IV PeriodontitisNCT04861493	LL-37	—	Completed	60	2021-02-23
Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.InfarctionNCT05485818	Thymosin Beta-4	Phase 2	Completed	62	2020-11-23
A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial InfarctionNCT01311518	Thymosin Beta-4	Phase 2	Withdrawn	0	2019-07
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3NCT03937882	Thymosin Beta-4	Phase 3	Completed	700	2019-05-24
Growth Hormone Dynamics and Cardiac Steatosis in HIVNCT03826160	Tesamorelin	—	Completed	23	2019-01-30
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular RiskNCT03375788	Sermorelin, Tesamorelin	Phase 2	Completed	51	2019-01-17
A Phase 1b Study of Thymosin Beta 4 in Healthy VolunteersNCT04555850	Thymosin Beta-4	Phase 1	Completed	30	2018-07-30
Tesamorelin to Improve Functional Outcomes After Peripheral Nerve InjuryNCT03150511	Tesamorelin	Phase 2	Recruiting	36	2018-06-01
Body Composition and Adipose Tissue in HIVNCT03226821	Tesamorelin	Phase 4	Terminated	6	2018-02-07
The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their CombinationNCT03878706	Liraglutide, MOTS-c	—	Recruiting	240	2017-11-03
The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive ImpairmentNCT02553603	Sermorelin, Tesamorelin	Phase 1	Completed	22	2017-07-18
A Phase 1a Study of Thymosin Beta 4 in Healthy VolunteersNCT04555824	Thymosin Beta-4	Phase 1	Completed	54	2017-07-17
Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected PersonsNCT02572323	Tesamorelin	Phase 2	Completed	73	2017-02-15
Study of Intranasal Octreotide (DP1038) in Healthy Adult VolunteersNCT03031535	Sermorelin	Phase 1	Completed	32	2017-01
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2NCT02974907	Thymosin Beta-4	Phase 3	Completed	601	2016-11
Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current InsomniaNCT02931474	Tesamorelin	Phase 2	Withdrawn	0	2016-10-06
Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.NCT02806414	LL-37	Phase 1/Phase 2	Completed	25	2016-07
Dehydroepiandrosterone Versus Growth Hormone in Women Undergoing ICSI With Expected Poor Ovarian ResponseNCT02736591	Sermorelin	Phase 3	Unknown	210	2016-06
Therapeutic Benefit of Preoperative Supplemental Vitamin D in Patients Undergoing Major Surgical Procedures.NCT02138591	LL-37	Phase 3	Withdrawn	0	2016-02
Cohort Of DEafness-gene ScreeningNCT06133946	MOTS-c	—	Active not recruiting	35920	2016-01-01
PCO-02 - Safety and Pharmacokinetics TrialNCT02637284	BPC-157	Phase 1	Unknown	42	2015-10
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1NCT02597803	Thymosin Beta-4	Phase 2/Phase 3	Completed	317	2015-09
Tesamorelin Effects on Liver Fat and Histology in HIVNCT02196831	Sermorelin, Tesamorelin	—	Completed	61	2015-07-01
Estradiol-Receptor Blockade in Older Men and WomenNCT02271282	Sermorelin	Phase 1	Completed	40	2014-12
Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CADNCT04027712	MOTS-c	—	Unknown	120	2014-01-01
Observational Longitudinal Study in Children Affected by Idiopathic Growth Hormone Deficiency (GHD)NCT02507245	Sermorelin	—	Completed	48	2014-01
Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone AnalogueNCT01632592	Sermorelin, Tesamorelin	—	Withdrawn	0	2014-01
Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®NCT01579695	Tesamorelin	—	Terminated	391	2013-02
Effects of Transcranial Magnetic Stimulation on Object RecognitionNCT01747200	Selank	—	Completed	13	2012-11-16
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®NCT01591902	Tesamorelin	Phase 4	Terminated	129	2012-06
Egrifta Replacement and Sleep Disordered BreathingNCT01788462	Tesamorelin	—	Withdrawn	0	2012-05
Effects of Smoking and Vitamin D3 on the Levels of Human Cathelicidin Peptide LL-37NCT03923218	LL-37	—	Completed	60	2011-12
Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle WastingNCT01388920	Tesamorelin	Phase 2	Terminated	3	2011-09
Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry EyeNCT01387347	Thymosin Beta-4	Phase 2	Completed	72	2011-08
Effects of Aminocaproic Acid (ACA) on Rosacea-specific InflammationNCT01398280	LL-37	EARLY_Phase 1	Completed	15	2011-07
Vitamin D in Ventilated ICU PatientsNCT01372995	LL-37	Phase 2	Completed	31	2011-07
Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the ElderlyNCT01410799	Sermorelin	Phase 2	Terminated	13	2011-05
Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal FunctionNCT01280344	Ipamorelin	Phase 2	Completed	320	2011-04
Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry EyeNCT01393132	Thymosin Beta-4	Phase 2	Completed	9	2011-03
VRS-317 in Adult Subjects With Growth Hormone DeficiencyNCT01359488	Sermorelin	Phase 1	Completed	50	2011-03
Effects of Growth Hormone Releasing Hormone in HIVNCT01263717	Sermorelin, Tesamorelin	—	Completed	54	2010-12
Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 SubjectsNCT01343641	MK-677	Phase 2	Withdrawn	0	2009-03
Effects of Short-term Growth Hormone in HIV-infected PatientsNCT00795210	Sermorelin, Tesamorelin	—	Completed	25	2009-02
Effect of Short Term Growth Hormone Releasing Hormone in Healthy MenNCT00850564	Sermorelin, Tesamorelin	—	Completed	15	2009-02
Vitamin D in Active Tuberculosis (TB) StudyNCT00788320	LL-37	—	Withdrawn	0	2008-10
Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are ObeseNCT00675506	Sermorelin, Tesamorelin	Phase 2	Completed	60	2008-07
Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive PatientsNCT02012556	Sermorelin, Tesamorelin	Phase 1	Completed	18	2008-05
A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy VolunteersNCT00743769	Thymosin Beta-4	Phase 1	Withdrawn	0	2008-04
Safety and Efficacy of Ipamorelin for Management of Post-Operative IleusNCT00672074	Ipamorelin	Phase 2	Completed	117	2008-04
Six Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the ElderlyNCT00807365	Sermorelin	Phase 2	Terminated	5	2007-12-17
A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal WoundsNCT00598871	Thymosin Beta-4	Phase 2	Terminated	12	2007-12
TH9507 Extension Study in Patients With HIV-Associated LipodystrophyNCT00608023	Sermorelin, Tesamorelin	Phase 3	Completed	263	2007-08
Sexually Dimorphic Effects of GHRH in Adult Growth Hormone TestingNCT00324064	Sermorelin	—	Completed	90	2007-07
Adult Growth Hormone Deficiency and Cardiovascular RiskNCT00720902	Sermorelin	Phase 4	Terminated	7	2007-02
Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD PatientsNCT00395291	MK-677	—	Completed	49	2006-08
Study of Thymosin Beta 4 in Patients With Venous Stasis UlcersNCT00832091	Thymosin Beta-4	Phase 2	Completed	72	2006-07
Study of Thymosin Beta 4 in Patients With Pressure UlcersNCT00382174	Thymosin Beta-4	Phase 2	Completed	72	2006-05
A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis BullosaNCT00311766	Thymosin Beta-4	Phase 2	Terminated	30	2006-02
SMART: Somatotrophics, Memory, and Aging Research TrialNCT00257712	Sermorelin, Tesamorelin	Phase 2	Completed	151	2006-02
A Study to Evaluate CJC 1295 in HIV Patients With Visceral ObesityNCT00267527	CJC-1295	Phase 2	Terminated	120	2005-12
Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)NCT00128115	MK-677	Phase 2	Terminated	83	2005-09
Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of FibromyalgiaNCT00116129	MK-677	Phase 2	Completed	64	2005-07
TH9507 in Patients With HIV-Associated LipodystrophyNCT00123253	Sermorelin, Tesamorelin	Phase 3	Completed	412	2005-06
The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart FailureNCT00791843	Sermorelin	Phase 2	Completed	3	2004-03
Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone DeficiencyNCT01060488	Sermorelin	Phase 3	Completed	69	2004-01
Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)NCT00074529	MK-677	Phase 2	Completed	512	2003-10
Safety Study of TH9507 in Subjects With Stable, Type 2 DiabetesNCT01264497	Tesamorelin	Phase 2	Completed	55	2002-02
Diagnosing Adult Growth Hormone DeficiencyNCT03018886	Sermorelin	—	Completed	160	2001-05
Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older AdultsNCT00474279	MK-677	Phase 1/Phase 2	Completed	72	1998-07
Growth Hormone Releasing Hormone (GHRH) Treatment for Age-Related Sleep DisturbancesNCT00000380	Sermorelin	—	Completed	—	1996-06
Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in AcromegalyNCT00004332	Sermorelin	—	Completed	148	1993-05

Citation: Synptide Peptide Clinical Trials, v1.0(synptide.com/datasets), sourced from ClinicalTrials.gov (public domain). The Synptide compound tagging is licensed CC BY 4.0. Registry data can lag real-world status — confirm on the source record before relying on it.